Patent EA-003245-B1 (EA)
Title: Benzamidine derivatives and the pharmaceutical composition based thereof
Inventor: SCHROMM KURT
IPC: C07C257/18
Filed: 1997-09-09
Abstract: 1. Benzamidine derivatives of general formula 1 wherein A denotes -OCH2CH2O-, -CH2O-, -CH2CH2CH2O-; R1 denotes branched or unbranched C1-6-alkyl, branched or unbranched C3-6-alkenyl, preferably allyl; R2 denotes hydrogen, branched or unbranched C1-6-alkyl, branched or unbranched C3-6-alkenyl, preferably allyl; R3 and R4, which may be identical or different, independently of one another denote hydrogen, branched or unbranched C1-6-alkyl, branched or unbranched C3-6-alkenyl, preferably allyl, C1-6-alkoxy, (C1-4alkyl)OC(O)O, hydroxyl, trifluomethyl, benzyloxyl, 2-hydroxyethoxyl, 2-morpholinoethoxyl or together denote a fused-on mono- or dinuclear ring system which may be wholly or partially conjugated and may optionally contain one or more heteroatoms selected from the group comprising oxygen, sulphur or nitrogen, which may be identical or different, which may optionally be substituted by OH, C1-4-alkoxy or C1-C4-alkyl, wherein said R3 can denote chlorine of fluorine; R5 denotes hydrogen, phenyl, -O-phenyl, -CR7R8-phenyl, -C(O)phenyl, -SO2-phenyl, -CH(OH)phenyl, wherein the phenyl ring may be substituted by OH, -C1-4-alkoxy, or -C(O)NR9R10; R6 denotes hydrogen, C1-6-alkoxycarbonyl or (C1-5alkyl)carbonyl or -C(O)-O-(C1-6-alkylene)-NR11R12 ; wherein R11 and R12, which may be identical or different, independently of one another denote hydrogen, branched or unbranched C1-8-alkyl; R7 and R8, which may be identical or different, denote hydrogen or branched or unbranched C1-8-alkyl; R9 and R10, which may be identical or different, independently of one another denote hydrogen, branched or unbranched C1-8-alkyl; optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates and in the form of the free bases or the corresponding acid addition salts with pharmacologically acceptable acids. 2. Compounds of general formula 1 according to claim 1, wherein A denotes -OCH2CH2O-, -CH2O-, -CH2CH2CH2O-; R1 denotes branched or unbranched C1-5-alkyl or allyl; R2 denotes hydrogen; R3 denotes hydrogen, C1-6-alkyl, methoxy, C2H5OC(O)O, hydroxy, chlorine, fluorine, trifluomethyl; R4 denotes hydrogen, methoxy, hydroxy; R3 and R4 together denote a fused-on benzene ring, a 3,4-dihydrocumarin system or a 1,3-dioxolane system which may be substituted hydroxyl, C1-C3-alkyl or methoxy-group; R5 denotes hydrogen, phenyl, O-phenyl, -CR7R8-phenyl, wherein the phenyl ring may be substituted by hydroxyl, methoxy-group, or -C(O)NR9R10; R6 denotes hydrogen or C1-4-alkoxycarbonyl or -C(O)-O-(CH2)2-N(C2H5)2; R7 and R8, which may be identical or different, independently of one another denote hydrogen, methyl or trifluomethyl; R9 and R10, which may be identical or different, denote hydrogen or branched or unbranched C1-C8-alkyl, optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates and in the form of the free bases or the corresponding acid addition salts with pharmacologically acceptable acids. 3. Benzamidine derivatives of general formula 1 according to claim 1, wherein A denotes -OCH2CH2O-, -CH2O-, -CH2CH2CH2O-; R1 denotes n-propyl, or allyl; R2 denotes hydrogene; R3 denotes benzyloxyl, 2-hydroxyethoxy, 2-morpholinoethoxy; R4 denotes n-propyl, n-propyl, methoxy; R5 denotes hydrogene; optionally in the form of the free bases or the corresponding acid addition salts with pharmacologically acceptable acids. 4. Pharmaceutical preparation, characterised in that it contains, at least, one compound according to claims 1-3 or the corresponding acid addition salts thereof together with excipients and/or carriers.